GENB.US Generate Biomedicines, Inc. Common Stock
- Market cap
- USD 1.55B
- P/E
- -
- P/B
- 3.53x
- ROE
- -75.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GENB.US undervalued?
Graham numberThe Graham number of Generate Biomedicines, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Generate Biomedicines, Inc. Common Stock fundamental analysis
No fundamental analysis for Generate Biomedicines, Inc. Common Stock yet.
Generate Biomedicines, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer mono…
Full company profileGenerate Biomedicines, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Generate Biomedicines, Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 20.5M | 31.9M | 23.7M |
| Gross Profit | 20.5M | 31.9M | 19.3M |
| Operating Income | -197M | -235M | -303M |
| EBITDA | -164M | -208M | -283M |
| Net Income | -174M | -203M | -288M |
| EPS | -1.36 | -4.06 | -2.24 |
| Balance Sheet | |||
| Total Assets | 518M | 330M | 516M |
| Total Liabilities | 953M | 953M | 135M |
| Shareholders' Equity | -435M | -616M | 381M |
| Cash & Short-term Investments | 394M | 221M | 404M |
| Total Debt | 77.0M | 68.5M | 75.3M |
| Cash Flow | |||
| Operating Cash Flow | -118M | -201M | -258M |
| Capital Expenditure | 3.45M | 3.51M | 9.16M |
| Free Cash Flow | -121M | -204M | -267M |
| Ratios | |||
| ROE | - | - | -75.7% |
| ROA | -33.5% | -61.5% | -55.9% |
| Net Profit Margin | -849.4% | -637.0% | -1,218.4% |
| Debt to Equity | - | - | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Generate Biomedicines, Inc. Common Stock dividends
Generate Biomedicines, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Generate Biomedicines, Inc. Common Stock
- Insiders 14.04%
- Institutions 80.60%
- Public & others 5.36%
- Shares outstanding 128M
- Free float 60.5M
Top funds holding GENB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.75M | 2.92% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 2.19M | 1.70% | +159.79% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.89M | 1.47% | +131.39% | Sep 2026 |
| ARK Genomic Revolution ETF | 1.64M | 1.28% | +0.58% | Oct 2026 |
| T. Rowe Price Health Sciences | 1.02M | 0.80% | -42.83% | Sep 2026 |
| Fidelity Growth Company K6 | 696K | 0.54% | +194.81% | Aug 2026 |
| JPMorgan Small Cap Growth A | 687K | 0.54% | +23.52% | Sep 2026 |
| JPM US Technology A dist USD | 661K | 0.51% | 0.00% | Sep 2026 |
| Fidelity Series Growth Company | 556K | 0.43% | +153.48% | Aug 2026 |
| ARK Venture D | 410K | 0.32% | +29.25% | Jul 2026 |
| Eaton Vance Worldwide Health Sci A | 309K | 0.24% | 0.00% | Sep 2026 |
| JPMorgan U.S. Tech Leaders ETF | 290K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 267K | 0.21% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Blend A | 218K | 0.17% | +22.26% | Sep 2026 |
| American Funds U.S. Sm & Md Cp Eq R-6 | 174K | 0.14% | 0.00% | Sep 2026 |
| ALPS Medical Breakthroughs ETF | 157K | 0.12% | 0.00% | Oct 2026 |
| Capital Group FG GOpp LUX ZL | 143K | 0.11% | 0.00% | Jul 2026 |
| Vanguard Russell 2000 ETF | 142K | 0.11% | +0.97% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 134K | 0.10% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 122K | 0.10% | -4.23% | Sep 2026 |
Top institutions holding GENB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 62.7M | 48.83% | 0.00% | Jun 2026 |
| FMR Inc | 5.22M | 4.07% | +23.81% | Jun 2026 |
| Capital World Investors | 4.22M | 3.28% | +5.28% | Jun 2026 |
| BRAIDWELL LP | 3.28M | 2.56% | -8.60% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.16M | 1.68% | +2.23% | Jun 2026 |
| NORGES BANK | 2.09M | 1.63% | 0.00% | Jun 2026 |
| ARCH VENTURE CORP | 1.94M | 1.51% | 0.00% | Jun 2026 |
| Harbourvest Partners, LLC | 1.72M | 1.34% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.66M | 1.29% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 1.42M | 1.11% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.41M | 1.10% | -52.17% | Jun 2026 |
| Deep Track Capital, LP | 1.33M | 1.04% | 0.00% | Jun 2026 |
| ARK Investment Management LLC | 1.28M | 1.00% | +157.74% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.13M | 0.88% | +762.59% | Jun 2026 |
| Harvard Management Co Inc | 1.11M | 0.87% | 0.00% | Jun 2026 |
| NVIDIA Corp | 833K | 0.65% | 0.00% | Jun 2026 |
| Davern Capital Partners, L.P. | 825K | 0.64% | +39.35% | Jun 2026 |
| Siren, L.L.C. | 736K | 0.57% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 735K | 0.57% | +521.60% | Jun 2026 |
| State Street Corp | 527K | 0.41% | 0.00% | Jun 2026 |
Generate Biomedicines, Inc. Common Stock company profile
- Company name
- Generate Biomedicines, Inc. Common Stock
- Ticker
- GENB.US
- Exchange
- USA Stocks
- Listed since
- Feb 27, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 312
- Fiscal year end
- December
- Address
- 101 South Street, Somerville, MA, United States, 02143
- Phone
- (888) 469-0055
- Website
- generatebiomedicines.com
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Generate Biomedicines, Inc. Common Stock management
10- Dr. Noubar B. Afeyan Ph.D.Co-founder & Independent Chair of the Board · born 1963
- Mr. Michael T. Nally M.B.A.CEO & Director · born 1976
- Dr. Jason E. Silvers J.D., M.D.President & CFO · born 1972
- Dr. Gevorg Grigoryan Ph.D.Co-Founder & CTO · born 1981
- Ms. Molly Gibson Ph.D.Co-Founder
- Dr. Aarif Khakoo M.B.A., M.D.Chief Scientific Officer · born 1971
- Mr. Sean B. W. Martin J.D.Secretary, Chief Legal Officer & General Counsel · born 1963
- Ms. Beth GrousChief People Officer · born 1968
- Dr. Daria Hazuda Ph.D.Senior Vice President of Discovery Strategy
- Mr. Sahm Nasseri M.B.A.Senior Vice President of Business Development & Strategy · born 1985